Comparison of the efficacy of three progestins in the treatment of simple endometrial hyperplasia without atypia

Gynecol Obstet Invest. 2011;72(1):10-4. doi: 10.1159/000321390. Epub 2011 Jan 25.

Abstract

Aim: To evaluate the treatment of endometrial hyperplasia (EH) with different progestins.

Methods: Eighty-two women with simple EH without atypia were included. Patients were offered oral progestagens and were randomized to one of three options for 3 months: medroxyprogesterone acetate (MPA, 10 mg/day), lynestrenol (LYN, 15 mg/day) and norethisterone (NET, 15 mg/day) for 10 days per cycle. Patients were reevaluated after treatment. Women diagnosed with proliferative and nonatypical EH at the second curettage were offered the same progestins for another 3 months. The primary outcome of the study was the proportion of women requiring further treatment.

Results: Of the 82 women, 46 (56.1%) received MPA (23.2%), LYN (13.4%) and NET (19.5%) therapy for another 3 months at the end of the first 3 months of treatment. The patients receiving MPA showed resolution in 36.7% of the cases versus 37% in the NET group. The highest resolution rate (56%) was observed in the LYN group, although there was no statistically significant difference between progestins regarding the proportion of women requiring further treatment (χ(2) = 2.608; p = 0.271).

Conclusion: It seems that the efficacies of oral progestins are similar at these dosages in simple EH without atypia.

Publication types

  • Comparative Study
  • Randomized Controlled Trial

MeSH terms

  • Adult
  • Endometrial Hyperplasia / drug therapy*
  • Female
  • Humans
  • Lynestrenol / administration & dosage
  • Medroxyprogesterone Acetate / administration & dosage
  • Middle Aged
  • Norethindrone / administration & dosage
  • Progestins / administration & dosage*
  • Prospective Studies
  • Treatment Outcome

Substances

  • Progestins
  • Medroxyprogesterone Acetate
  • Lynestrenol
  • Norethindrone